Noticias y Actividades de Tris Pharma
Ejecutivos
Ver el organigrama con sus 17 ejecutivos principales
Biografías más buscadas en Tris Pharma
- Ketan Mehta, Chief Executive Officer and President
- Peter Ciano, Chief Financial Officer and Senior Vice President, Co...
- Cheryl Patnick, Chief Administrative Officer
Recientes movimientos de ejecutivos en Tris Pharma
- Manesh Naidu que ha sido Vice President, Marketing, ha ascendido a Chief Commercial Officer (noticia publicada el 17 de septiembre de 2024).
Crear su alerta
para seguir los movimientos de los ejecutivos en Tris Pharma.
Farmacia
Tris Pharma tiene 1.833 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Eli Lilly (Estados Unidos).
Popular M&A news in Farmacia
- Imbria Pharmaceuticals acaba de anunciar una recaudación de fondos de 58 millones de dólares. (publicado el 10 de abril de 2025).
- Clario ha NRx Pharmaceuticals adquirido (publicado el 18 de marzo de 2025).
- Knight Therapeutics has announced the acquisition of Paladin Labs (publicado el 12 de marzo de 2025).
Otros contactos sugeridos en el sector Farmacia
Noticias
Últimos comunicados de prensa de Tris Pharma
- Media Highlights and Coverage | Tris Pharma
- Tris Pharma Launches Digital Health Business to Develop and Commercialize Digital Products for ADHD | Tris Pharma
- Tris Pharma Appoints Michael Magee as Vice President, Quality & Compliance | Tris Pharma
- Tris Pharma Appoints Franchesca Fowler to Chief Compliance Officer and Vice President, General Counsel | Tris Pharma
- Tris Pharma Partners with Perigon Pharmacy 360 to Enhance Access to DYANAVEL® XR Tablets for the Treatment of Attention Deficit Hyperactivity Disorder | Tris Pharma
- Tris Pharma Secures First ex-US Authorizations for Quillivant ER Oral Suspension and Quillivant ER Chewable Tablet for the Treatment of Attention Deficit Hyperactivity Disorder | Tris Pharma
- Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference | Tris Pharma
- Tris Pharma Awarded Five-Year Grant of Up to $16.6M From the NIH's National Institute on Drug Abuse to Advance Cebranopadol for the Treatment of Opioid Use Disorder | Tris Pharma
- Tris Pharma Expands Leadership Team as Company Broadens Commercial Portfolio and Progresses Clinical Pipeline | Tris Pharma
- Tris Pharma Announces FDA Approval of DYANAVEL® XR (amphetamine) Once-Daily Extended-Release Oral Tablets, CII, for ADHD | Tris Pharma
- View more press releases Close
Redes sociales sobre Tris Pharma
- Tris Pharma en Wikipedia, Google News y Yahoo Finance
- Tris Pharma en LinkedIn, Twitter y YouTube
